Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MPO drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Active Site Mutants) | MPO Recombinant Protein (wild-type and mutant variants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation and heme incorporation. | View MPO Products |
| Gene Delivery | MPO Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View MPO Products |
| Benchmark Ab | Anti-MPO (Research Grade / Biosimilar Control). Recombinant monoclonal for assay calibration and positive control. | View MPO Products |
| Validator | MPO siRNA Set. For knockdown verification and specificity controls. | View MPO Products |
| Related Target: ELANE | Neutrophil Elastase. Co-released azurophilic granule protease; synergistic inflammation pathway. | View ELANE Products |
| Related Target: NOX2 | NADPH oxidase component, generates H2O2 utilized by MPO. | View NOX2 Products |
| Related Target: EPO | Eosinophil Peroxidase. Peroxidase homolog for selectivity counter-screening. | View EPO Products |
| Related Target: PRTN3 | Proteinase 3. Azurophilic granule serine protease; vasculitis-associated with MPO. | View PRTN3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Peroxidase family selectivity (avoiding TPO/EPO/LPO cross-inhibition) | Homolog panel proteins (TPO, EPO, LPO) strictly verified by mass spec; Human/Mouse/Cyno orthologs available. |
| Enzymatic activity & inhibition kinetics | High-purity active MPO with correct heme incorporation; Endotoxin controlled for oxidation assays. |
| Mechanism-based inhibition validation | Active site mutants (e.g., R239E, D94N) available as negative controls. |
| False positives in cellular models | Validated siRNA included for target-specificity checks. |
| Lack of validated diagnostics controls | Sequence-verified recombinant benchmark antibodies for precise standard curves. |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno MPO ortholog proteins available with >95% purity. |
Live MPO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MPO-targeted therapeutics is intensifying, driven by its central role in oxidative stress-related tissue damage, cardiovascular disease, and neurodegenerative conditions. While first-generation inhibitors (e.g., AstraZeneca's AZD3241/Verdiperstat, licensed to Biohaven for multiple system atrophy) faced selectivity and efficacy hurdles, the next wave of R&D focuses on highly selective, irreversible small-molecule inhibitors with improved brain penetration and combination strategies with anti-inflammatory agents. Beyond direct inhibition, MPO serves as a critical diagnostic biomarker for ANCA vasculitis and cardiovascular risk stratification, boosting demand for high-purity antigens and reference antibodies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Biohaven, AstraZeneca, Pfizer | Multiple System Atrophy, Heart Failure, Atherosclerosis, ANCA Vasculitis | Enzymatic inhibition assay (need high-purity active MPO with native glycosylation for kinetic studies) |
| Diagnostic / Imaging mAb | Abbott, Siemens Healthineers, IVD Developers | Cardiovascular Risk Stratification, ANCA Vasculitis | Immunogenicity testing & capture assays (need recombinant MPO antigen and benchmark antibodies) |
| Biologic / Peptide (Emerging) | Emerging Biotech, Academic Groups | Ischemia-Reperfusion Injury, Sepsis | Epitope mapping & neutralization assays (need mutant variants and homolog panel) |
Key Mutations and Functional Insights
Relevant naturally occurring mutations in MPO (source: UniProt P05164) provide insights for assay development and variant screening:
- rs7208693 (dbSNP): A polymorphism linked to altered enzyme activity; relevant in population studies of oxidative stress.
- rs78950939 (dbSNP): Affects proteolytic processing and secretion; critical for understanding MPO biosynthesis and for designing assays that distinguish pro-form from mature enzyme.
- rs56378716 (dbSNP): Implicated in modulation of MPO function; potential biomarker in inflammatory conditions.
TarMart offers recombinant wild-type and select mutant MPO proteins (including active-site mutants such as R239E and D94N) to support functional studies, inhibitor screening, and mechanism-of-action assays.
Cross-Reference: Related Myeloperoxidase Family Targets
For selectivity profiling, TarMart provides a full panel including EPO (eosinophil peroxidase), TPO (thyroid peroxidase), and LPO (lactoperoxidase). Comparing inhibitory profiles across this panel is essential to avoid off-target toxicity, especially against TPO which can lead to hypothyroidism.